Schrieks IC, et al. - Researchers examined associations of adiponectin and free fatty acids (FFAs) and major adverse cardiovascular events (MACEs) and death in patients with acute coronary syndrome (ACS) and type 2 diabetes utilizing data from the AleCardio trial, which compared the PPAR-α/γ agonist aleglitazar with placebo. They found that adiponectin was prospectively associated with MACEs and death in patients with type 2 diabetes and ACS, and an increase in adiponectin from baseline was directly related to death, which was in contrast to prior observational data for incident coronary heart disease (CHD). It was noted that adiponectin has different effects in type 2 diabetic patients and ACS than in populations without prevalent cardiovascular disease. Findings revealed that FFAs were directly linked with adverse outcomes.